Be sure to check our sister interview main ratings news website

Poolbeg Pharma receives US Patent Office Allowance for Immunomodulator II

Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

This AIM-traded firm said the development pertained to POLB 001, a potent phase II-ready p38 MAP kinase inhibitor with promising applications across various disease domains.

It said the approved claims by the US Patent Office encompassed a class of drugs, including POLB 001, intended for the treatment of hypercytokinemia, or cytokine storm, and prevention of hypercytokinemia post-immune response activation, applicable to cytokine storms induced by any disease indication.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

The Medicine of Tomorrow

23rd January 2025

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

9th January 2025

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

21st November 2024

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

20th November 2024

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

14th November 2024

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

5th November 2024

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

28th October 2024

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

24th October 2024

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.